Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

At the moment, the company is developing novel therapeutic approaches for patients with underserved heart issues, such as ...